FROM SINGAPORE TO BASEL: DATA COLLABORATION FOR ALZHEIMER’S

At Switzerland Innovation Park Basel Area, Holmusk established its European base and entered a local research collaboration to advance Alzheimer’s research with real-world evidence.

«Proximity matters. Basel, with its large ecosystem of global leaders in life sciences, offers multiple partnership opportunities and allows direct access to expand our business into Germany or France.»

Nawal Roy

Founder and CEO, Holmusk

Mental and neurological healthcare generates vast amounts of information, but much of it remains fragmented or hidden in unstructured clinical notes. This makes it difficult for researchers to compare symptoms, treatments and outcomes. Holmusk addresses this challenge by transforming de-identified clinical information into research-ready real-world evidence.

Founded in Singapore, Holmusk has built the world’s largest real-world clinical data platform  for neurology and psychiatry. Its flagship platform, NeuroBlu  uniquely integrates longitudinal patient data with itemized outcome scales, clinical notes, lab results, demographics, prescription history and Datavant privacy tokens. Natural-language-processing and large language models extract relevant information from clinical notes and convert it into standardised labels, enabling researchers to phenotype patients and investigate sub-populations, treatment pathways, disease progression and outcomes. Today, NeuroBlu represents more than 46 million patients with over 20 years of longitudinal data.

More importantly, NeuroBlu provides the foundation for the next generation of AI-driven disease models. As multimodal clinical data continue to expand, NeuroBlu is designed to evolve into foundational "NeuroLLM". A disease-specific foundation models capable of representing the biology and clinical trajectory of neurological and psychiatric disorders such as Alzheimer’s Disease. Such models are expected to fundamentally transform drug discovery, clinical trial design, and precision medicine, making high-quality longitudinal data one of the most valuable strategic assets in the future of healthcare AI.

In 2021, Holmusk established its Basel office at the Novartis Campus site of Switzerland Innovation Park Basel Area—its seventh international office and first in Europe. Basel Area Business & Innovation supported the company in setting up its regional presence. The location gave Holmusk access to multilingual specialists, global life sciences organisations and healthcare partners, while also providing a gateway to Germany and France.

The value of this ecosystem became tangible shortly after the company’s arrival. In 2021, Holmusk secured a strategic investment from Novartis dRx Capital and University Department of Geriatric Medicine FELIX PLATTER in Basel announced a research collaboration to explore how real-world evidence and machine learning could advance Alzheimer’s disease research. The partners planned to combine Holmusk’s data-analysis capabilities with the clinical expertise of the FELIX PLATTER Memory Clinic to analyse clinical-trial and real-world data, model disease progression and generate hypotheses for future studies. The collaboration illustrates how an international health-data company can establish itself in Basel and connect with specialised local research and healthcare expertise.

Key Facts

  • 0

    Patients represented in Holmusk’s electronic health record platform NeuroBlu (July 2026)

  • 0

    Longitudinal real-world data, including itemized scales and clinical notes

  • 0

    Basel office established at the Novartis Campus site

Explore More Success Stories